



SAFETY DATA SHEET

1. Identification

Product identifier VOLIBRIS TABLETS

Other means of identification

Synonyms VOLIBRIS 5 MG TABLETS * VOLIBRIS 10 MG TABLETS * AMBRISENTAN, FORMULATED PRODUCT

Recommended use of the chemical and restrictions on use

Recommended use Medicinal Product.

This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient.

Restrictions on use No other uses are advised.

Details of manufacturer or importer

Manufacturer

GlaxoSmithKline Australia
1061 Mountain Highway
Melbourne, Victoria 3155
Australia
Australia General Information (Normal Business Hours): (03) 9721 6000

TRANSPORTATION EMERGENCY NUMBERS
(available 24hrs/7days: multi-language response)
Australia Toll Free +(61) 2 9037 2994
International Toll Call +(1) 703 527 3887

2. Hazard(s) identification

Classification of the hazardous chemical

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Label elements, including precautionary statements

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Other hazards which do not result in classification

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

3. Composition/information on ingredients

Mixture

Identity of chemical ingredients	CAS number and other unique identifiers	Concentration of ingredients
MICROCRYSTALLINE CELLULOSE	9004-34-6	< 25
AVICEL PH MICROCRYSTALLINE CELLULOSE		
ALPHA-CELLULOSE		
AVICEL PH101		
AVICEL PH102		
AVICEL PH103		
AVICEL PH105		
AVICEL PH112		
AVICEL PH200		
CELLULOSE (8CI9CI)		
CELLULOSE CRYSTALLINE		
CELLULOSE, FOOD GRADE		
CRYSTALLINE CELLULOSE		

AMBRISENTAN (S)-2-(4,6-DIMETHYL-PYRIMIDIN-2-YLOXY)-3-METHOXY-3,3-DIPHENYLPR OPANOIC ACID BSF 208075 GSK1325760	177036-94-1	3.4 - < 7
MAGNESIUM STEARATE STEARIC ACID, MAGNESIUM SALT MAGNESIUM DISTEARATE DIBASIC MAGNESIUM STEARATE MAGNESIUM DISTEARATE, PURE	557-04-0	< 1
Talc TALCUM, NON-ASBESTOS FORM Talc HYDROUS MAGNESIUM SILICATE	14807-96-6	< 1
Titanium dioxide TITANIUM OXIDE TITANIUM(IV) OXIDE TITANIUM PEROXIDE (TiO2) PIGMENT WHITE 6	13463-67-7	< 1
Other components below reportable levels		60 - < 70

4. First-aid measures

Description of necessary first aid measures

Inhalation	Move to fresh air. If breathing is difficult, trained personnel should give oxygen. Call a physician if symptoms develop or persist. Under normal conditions of intended use, this material is not expected to be an inhalation hazard.
Skin contact	Immediately flush skin with plenty of water. Take off contaminated clothing and wash before reuse. Get medical attention if symptoms occur.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
Ingestion	If swallowed, rinse mouth with water (only if the person is conscious). If ingestion of a large amount does occur, call a poison control centre immediately. Do not induce vomiting without advice from poison control center.
Personal protection for first-aid responders	In the case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves.
Symptoms caused by exposure	None known. The following adverse effects have been noted with therapeutic use of this material: headache; flushing; dizziness.
Medical attention and special treatment	No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre.

5. Fire-fighting measures

Extinguishing media

Suitable extinguishing media	Water. Foam. Dry chemical powder. Carbon dioxide (CO2).
Unsuitable extinguishing media	None known.

Specific hazards arising from the chemical During fire, gases hazardous to health may be formed.

Special protective equipment and precautions for fire fighters Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Fire fighting equipment/instructions Move containers from fire area if you can do so without risk.

Hazchem Code Not available.

General fire hazards No unusual fire or explosion hazards noted.

Specific methods Use standard firefighting procedures and consider the hazards of other involved materials.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

For non-emergency personnel Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Keep out of low areas. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. For personal protection, see section 8.

For emergency responders Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the SDS.

Environmental precautions Avoid discharge into drains, water courses or onto the ground.

Methods and materials for containment and cleaning up Stop the flow of material, if this is without risk. Prevent entry into waterways, sewer, basements or confined areas. Following product recovery, flush area with water. For waste disposal, see section 13 of the SDS.

7. Handling and storage

Precautions for safe handling Observe good industrial hygiene practices.

Conditions for safe storage, including any incompatibilities Store in original tightly closed container. Store away from incompatible materials (see Section 10 of the SDS).

8. Exposure controls and personal protection

Control parameters Follow standard monitoring procedures.

Occupational exposure limits

GSK

Components	Type	Value	Note
AMBRISANTAN (CAS 177036-94-1)	8 HR TWA	20 mcg/m3	
	OHC	3	Reproductive hazard
MICROCRYSTALLINE CELLULOSE (CAS 9004-34-6)	OHC	1	

Australia. National Workplace OELs (Workplace Exposure Standards for Airborne Contaminants, Appendix A)

Components	Type	Value	Form
MAGNESIUM STEARATE (CAS 557-04-0)	TWA	10 mg/m3	Inhalable dust.
MICROCRYSTALLINE CELLULOSE (CAS 9004-34-6)	TWA	10 mg/m3	Inhalable fibers.
Talc (CAS 14807-96-6)	TWA	2.5 mg/m3	
Titanium dioxide (CAS 13463-67-7)	TWA	10 mg/m3	Inhalable dust.

Australia. OELs. (Adopted National Exposure Standards for Atmospheric Contaminants in the Occupational Environment)

Components	Type	Value	Form
MAGNESIUM STEARATE (CAS 557-04-0)	TWA	10 mg/m3	Inspirable dust.
MICROCRYSTALLINE CELLULOSE (CAS 9004-34-6)	TWA	10 mg/m3	Inspirable dust.
Talc (CAS 14807-96-6)	TWA	2.5 mg/m3	
Titanium dioxide (CAS 13463-67-7)	TWA	10 mg/m3	Inspirable dust.

US. ACGIH Threshold Limit Values

Components	Type	Value	Form
MAGNESIUM STEARATE (CAS 557-04-0)	TWA	10 mg/m3	
MICROCRYSTALLINE CELLULOSE (CAS 9004-34-6)	TWA	10 mg/m3	
Talc (CAS 14807-96-6)	TWA	2 mg/m3	Respirable fraction.
Titanium dioxide (CAS 13463-67-7)	TWA	10 mg/m3	

UK. EH40 Workplace Exposure Limits (WELs)

Components	Type	Value	Form
MICROCRYSTALLINE CELLULOSE (CAS 9004-34-6)	STEL	20 mg/m3	Inhalable dust.
	TWA	4 mg/m3	Respirable dust.
		10 mg/m3	Inhalable dust.
Talc (CAS 14807-96-6)	TWA	1 mg/m3	Respirable dust.
Titanium dioxide (CAS 13463-67-7)	TWA	4 mg/m3	Respirable.
		10 mg/m3	Inhalable

Biological limit values No biological exposure limits noted for the ingredient(s).

Exposure guidelines

Appropriate engineering controls General ventilation normally adequate.

Individual protection measures, for example personal protective equipment (PPE)

Eye/face protection If contact is likely, safety glasses with side shields are recommended.

Skin protection

Hand protection For prolonged or repeated skin contact use suitable protective gloves.

Other

Wear suitable protective clothing as protection against splashing or contamination.

Respiratory protection

When workers are facing concentrations above the exposure limit they must use appropriate certified respirators.

Thermal hazards

Wear appropriate thermal protective clothing, when necessary.

Hygiene measures

Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants. For advice on suitable monitoring methods, seek guidance from a qualified environment, health and safety professional. New or expectant mothers might be at greater risk from overexposure. Risk assessments must take this into consideration. Female employees anticipating pregnancy or with a confirmed pregnancy must be encouraged to notify an occupational health professional or their line manager. This will act as the trigger for individual re-assessment of the employee's work practices.

9. Physical and chemical properties**Appearance**

Physical state Solid.

Form Tablet.

Colour Not available.

Odour Not available.

Odour threshold Not available.

pH Not available.

Melting point/freezing point Not available.

Initial boiling point and boiling range Not available.

Flash point Not available.

Evaporation rate Not available.

Flammability (solid, gas) Not available.

Upper/lower flammability or explosive limits

Flammability limit - lower (%) Not available.

Flammability limit - upper (%) Not available.

Explosive limit - lower (%) Not available.

Explosive limit - upper (%) Not available.

Vapour pressure Not available.

Vapour density	Not available.
Relative density	Not available.
Solubility(ies)	
Solubility (water)	Not available.
Partition coefficient (n-octanol/water)	Not available.
Auto-ignition temperature	Not available.
Decomposition temperature	Not available.
Viscosity	Not available.

10. Stability and reactivity

Reactivity	The product is stable and non-reactive under normal conditions of use, storage and transport.
Chemical stability	Material is stable under normal conditions.
Possibility of hazardous reactions	No dangerous reaction known under conditions of normal use.
Conditions to avoid	Contact with incompatible materials.
Incompatible materials	Strong oxidising agents. Fluorine.
Hazardous decomposition products	None known. Irritating and/or toxic fumes and gases may be emitted upon the product's decomposition.

11. Toxicological information

Information on possible routes of exposure

Inhalation	Under normal conditions of intended use, this material is not expected to be an inhalation hazard.
Skin contact	Health injuries are not known or expected under normal use. Dust or powder may irritate the skin.
Eye contact	Health injuries are not known or expected under normal use. Dust or powder may irritate eye tissue.
Ingestion	Health injuries are not known or expected under normal use. May be harmful if swallowed. However, ingestion is not likely to be a primary route of occupational exposure.
Symptoms related to exposure	None known. The following adverse effects have been noted with therapeutic use of this material: headache; flushing; dizziness.

Acute toxicity	Health injuries are not known or expected under normal use. May be harmful if swallowed.
-----------------------	--

Components	Species	Test results
AMBRISENTAN (CAS 177036-94-1)		
Acute		
<i>Oral</i>		
LD50	Rat	>= 3160 mg/kg
MAGNESIUM STEARATE (CAS 557-04-0)		
Acute		
<i>Oral</i>		
LD50	Rat	> 2000 mg/kg
MICROCRYSTALLINE CELLULOSE (CAS 9004-34-6)		
Acute		
<i>Dermal</i>		
LD50	Rabbit	> 2000 mg/kg
<i>Oral</i>		
LD50	Rat	> 2000 mg/kg
Titanium dioxide (CAS 13463-67-7)		
Acute		
<i>Inhalation</i>		
LC50	Rat	6820 mcg/m3
<i>Oral</i>		
LD50	Rat	> 24 g/kg

Components	Species	Test results
Chronic		
<i>Inhalation</i>		
LOEC	Rat	8.6 mg/m3, 1 years TiO2 accumulated in interstitial macrophages, aggregated interstitial cells and particle laden macrophages in lymphoid tissue.
NOAEC	Rat	250 mg/m3, 2 years Highest dose 5 mg/m3, 24 months
Subacute		
<i>Inhalation</i>		
LOEL	Rat	0.1 - 35 mg/m3, 4 weeks Mild macrophage hyperplasia, no change in bronchio-alveolar lavage fluid.
NOAEC	Guinea pig	26 mg/m3, 3 weeks No evidence of significant inflammation in respiratory tract.
<i>Oral</i>		
NOAEL	Rat	100000 ppm, 14 Day Dietary study, highest dose tested.
Subchronic		
<i>Inhalation</i>		
LOEC	Rat	3.2 - 20 mg/m3, 8 min Accumulation of TiO2 in macrophages and evidence of pulmonary inflammation.

* Estimates for product may be based on additional component data not shown.

Skin corrosion/irritation Health injuries are not known or expected under normal use. Prolonged skin contact may cause temporary irritation.

Irritation Corrosion - Skin
TITANIUM DIOXIDE

0, Literature data
Result: Non-irritant
Species: Guinea pig
0, Literature data
Result: Non-irritant
Species: Human
Acute dermal irritation; OECD 404, Literature data
Result: Non-irritant
Species: Rabbit
Reconstituted Human Epidermis (RHE)
Result: Negative - Not likely to be a significant irritant.

AMBRISANTAN

Irritation Corrosion - Skin: P.I.I. value
MAGNESIUM STEARATE

0

Serious eye damage/irritation Health injuries are not known or expected under normal use. Dust or powder may irritate eye tissue.

Eye

TITANIUM DIOXIDE

OECD 405, Literature data
Result: Mild irritant
Species: Rabbit
Reconstituted Human Corneal Epithelium (HCE)
Result: Negative; not likely to be a severe irritant

AMBRISANTAN

Eye / Kay and Calandra class - Intact
MAGNESIUM STEARATE

4
Recovery Period: 2 days

Respiratory or skin sensitisation

Respiratory sensitisation Not available.

Skin sensitisation Health injuries are not known or expected under normal use.

Sensitisation

TITANIUM DIOXIDE

5 % Optimisation Test, Literature data - Vehicle: petrolatum

Result: negative

Species: Guinea pig

Test Duration: 48 hour exposure

AMBRISENTAN

OECD 429 / Local Lymph Node Assay, Maximum concentration = 50%; vehicle = DMF

Result: negative

Species: Mouse

TITANIUM DIOXIDE

Patch test, Literature data

Result: negative

Species: Human

Germ cell mutagenicity

Health injuries are not known or expected under normal use. No data available to indicate product or any components present at greater than 0.1% are mutagenic or genotoxic.

Mutagenicity

AMBRISENTAN

Ames Assay, GLP assay

Result: negative

TITANIUM DIOXIDE

Ames, Literature data

Result: negative

AMBRISENTAN

Chromosomal Aberration Assay In Vitro

Result: positive

TITANIUM DIOXIDE

Micronucleus Assay in vitro, CHO cells, Literature data

Result: negative

Micronucleus Assay in vitro, cultured human peripheral lymphocytes, Literature data

Result: positive

AMBRISENTAN

Micronucleus Assay, GLP assay

Result: negative

Species: Rat

TITANIUM DIOXIDE

Syrian Hamster Embryo (SHE) cell transformation assay

Result: negative

AMBRISENTAN

Unscheduled DNA Synthesis in vivo

Result: negative

Species: Rat

TITANIUM DIOXIDE

WIL2-NS HPRT/ t-Thioguanidine - Human B-Cell

lymphoblastoid, Literature data

Result: positive

Carcinogenicity

Health injuries are not known or expected under normal use. Contains a material (titanium dioxide) classified as a carcinogen by external agencies. Carcinogenic activity was seen in inhalation studies using laboratory animals. High concentrations or doses administered over an extended period of time were required to produce adverse effects.

TITANIUM DIOXIDE

0.5 mg/m3, Literature data

Result: negative

Species: Rat

Test Duration: 24 months

0.72 - 14.8 mg/m3, Literature data

Result: negative

Species: Mouse

10 - 250 mg/m3, Dietary study - Literature data.

Result: Inflammation at all doses with alveolar/bronchiolar adenoma at the highest concentration.

Species: Rat

Test Duration: 24 months

25000 - 50000 ppm, Dietary study

Result: negative

Species: Mouse

25000 - 50000 ppm, Dietary study - Literature data.

Result: negative

Species: Rat

7.2 - 14.8 mg/m3, Literature data

Result: Lung tumour

Species: Rat

Test Duration: 24 months

ACGIH Carcinogens

MAGNESIUM STEARATE (CAS 557-04-0)

A4 Not classifiable as a human carcinogen.

Talc (CAS 14807-96-6)

A4 Not classifiable as a human carcinogen.

Titanium dioxide (CAS 13463-67-7) A4 Not classifiable as a human carcinogen.
IARC Monographs. Overall Evaluation of Carcinogenicity

Titanium dioxide (CAS 13463-67-7) 2B Possibly carcinogenic to humans.

Reproductive toxicity	Suspected of damaging fertility or the unborn child.
Specific target organ toxicity - single exposure	None known.
Specific target organ toxicity - repeated exposure	None known.
Aspiration hazard	Not available.
Chronic effects	Prolonged exposure may cause chronic effects.
Other information	Caution - Pharmaceutical agent. Occupational exposure to the substance or mixture may cause adverse effects.

12. Ecological information

Ecotoxicity Not expected to be harmful to aquatic organisms.

Components		Species	Test results
AMBRISENTAN (CAS 177036-94-1)			
Aquatic			
Acute			
Algae	EC50	Algae	10 - 100 mg/l, 96 hours QSAR Estimate
Crustacea	EC50	Daphnia	10 - 100 mg/l, 48 hours QSAR Estimate
Fish	EC50	Fish	10 - 100 mg/l, 96 hours QSAR Estimate
MAGNESIUM STEARATE (CAS 557-04-0)			
Aquatic			
Acute			
Fish	EC50	Orange-red killfish (Adult Oryzias latipes)	130 mg/l, 96 hours
Talc (CAS 14807-96-6)			
Aquatic			
Acute			
Fish	EC50	Zebra fish (Adult Brachydanio rerio)	> 100 g/l, 24 hours Static renewal test
Titanium dioxide (CAS 13463-67-7)			
Aquatic			
Acute			
Crustacea	EC50	Water flea (Daphnia magna)	> 1000 mg/l, 48 hours Static test

* Estimates for product may be based on additional component data not shown.

Persistence and degradability

Photolysis

Half-life (Photolysis-atmospheric)

MAGNESIUM STEARATE 17 Hours Estimated

UV/visible spectrum wavelength

MAGNESIUM STEARATE 210 nm

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

MAGNESIUM STEARATE 77 %, 28 days BOD

Percent degradation (Aerobic biodegradation-ready)

MAGNESIUM STEARATE 95 %, 22 days Sturm test

Percent degradation (Aerobic biodegradation-soil)

MAGNESIUM STEARATE 50 %, 13 days

Bioaccumulative potential

Partition coefficient

n-octanol / water (log Kow)

AMBRISANTAN 1.2 (Measured).

**Bioconcentration factor
(BCF)**

MAGNESIUM STEARATE > 9999 Estimated

Mobility in soil No data available for this product.

Adsorption

Soil/sediment sorption - log K_{oc}

MAGNESIUM STEARATE 5.86 Estimated

Mobility in general Not available.

Other adverse effects Not available.

13. Disposal considerations

Disposal methods Collect and reclaim or dispose in sealed containers at licensed waste disposal site. Do not discharge into drains, water courses or onto the ground. Dispose in accordance with all applicable regulations.

Residual waste Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions). Avoid discharge into water courses or onto the ground.

Contaminated packaging Empty containers should be taken to an approved waste handling site for recycling or disposal. Since emptied containers may retain product residue, follow label warnings even after container is emptied.

14. Transport information

ADG

Not regulated as dangerous goods.

RID

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code Not available.

15. Regulatory information

Safety, health and environmental regulations

National regulations This Material Safety Data Sheet was prepared in accordance with the Australia National Code of Practice for the Preparation of Material Safety Data Sheets (NOHSC: 2011.)

Australia Medicines & Poisons Appendix A

Poisons schedule number not allocated.

Australia Medicines & Poisons Appendix B

Poisons schedule number not allocated.

Australia Medicines & Poisons Appendix C

Poisons schedule number not allocated.

Australia Medicines & Poisons Appendix D

AMBRISSENTAN (CAS 177036-94-1)

for human use Poisons available only from or on the order of a specialist physician and for which the prescriber must, where the patient is a woman of child bearing age: (a) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and (b) advise the patient to avoid becoming pregnant during or for a period of 3 months after completion of treatment.

Australia Medicines & Poisons Appendix E

Poisons schedule number not allocated.

Australia Medicines & Poisons Appendix F

AMBRISANTAN (CAS 177036-94-1)

applies to all preparations in any concentration WARNING - Causes Birth Defects., See a doctor if you are pregnant or diabetic., Do not become pregnant during use or within (Insert number of months as per approved product information) month(s) of stopping treatment.

Australia Medicines & Poisons Appendix G

Poisons schedule number not allocated.

Australia Medicines & Poisons Appendix H

Poisons schedule number not allocated.

Australia Medicines & Poisons Appendix I

Poisons schedule number not allocated.

Australia Medicines & Poisons Appendix J

Poisons schedule number not allocated.

Australia Medicines & Poisons Appendix K

Poisons schedule number not allocated.

Australia Medicines & Poisons Schedule 2

Poisons schedule number not allocated.

Australia Medicines & Poisons Schedule 3

Poisons schedule number not allocated.

Australia Medicines & Poisons Schedule 4

Poisons schedule number not allocated.

Australia Medicines & Poisons Schedule 5

Poisons schedule number not allocated.

Australia Medicines & Poisons Schedule 6

Poisons schedule number not allocated.

Australia Medicines & Poisons Schedule 7

Poisons schedule number not allocated.

Australia Medicines & Poisons Schedule 8

Poisons schedule number not allocated.

Australia Medicines & Poisons Schedule 9

Poisons schedule number not allocated.

High Volume Industrial Chemicals (HVIC)

Talc (CAS 14807-96-6)

100000 - 999999 TONNES See the regulation for additional information.

Titanium dioxide (CAS 13463-67-7)

100000 - 999999 TONNES See the regulation for additional information.

Importation of Ozone Depleting Substances (Customs(Prohibited imports) Regulations 1956, Schedule 10)

Not listed.

National Pollutant Inventory (NPI) substance reporting list

Not listed.

Prohibited Carcinogenic Substances

Not regulated.

Prohibited Substances (National Model Regulation for the control of Workplace Hazardous Substances, Schedule 2 NOHSC:1005 (1994) as amended)

Not listed.

Restricted Importation of Organochlorine Chemicals (Customs(Prohibited Imports) Regulations 1956, Schedule 9)

Not listed.

Restricted Carcinogenic Substances

Not regulated.

International regulations

Stockholm Convention

Not applicable.

Rotterdam Convention

Not applicable.

Kyoto protocol

Not applicable.

Montreal Protocol

Not applicable.

Basel Convention

Not applicable.

International Inventories

Country(s) or region	Inventory name	On inventory (yes/no)*
Australia	Australian Inventory of Chemical Substances (AICS)	No
Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	No
China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	No
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	No
Korea	Existing Chemicals List (ECL)	No
New Zealand	New Zealand Inventory	No
Philippines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	No
United States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	No

*A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)

A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

16. Other information

Issue date	05-November-2014
Revision date	05-November-2014
References	GSK Hazard Determination
Disclaimer	The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.
Revision Information	Product and Company Identification: Product and Company Identification Composition / Information on Ingredients: Ingredients Exposure Controls / Personal Protection: Physical & Chemical Properties: Regulatory Information: United States GHS: Classification